khec Market watch: Index falls to 39,500 as selling continues

[CharlesteApect]

Ifkl IU Research Reveals Link between Molecular Mechanisms in Prostate Cancer and Ewing s sarcoma
ISLAMABAD:The Sensitive Price Indicator (SPI) for the week ended July 21 registered an increase of 0.25% for the combined income group, going up from 219.41 points in the previous week to 219.96 in the wee nb k under review. Compared to the corresponding week of last year, the SPI for the combined income group rose 2.18%. The SPI for the lowest income group increased 0.37% compared to the previous week. The index for the group stood at 211.02 points against 210.24 i nb 9060 n the previous week, according to provisional figures released by the Pakistan Bureau of Statistics. During the week, average prices of 16 items rose in a selected basket of goods, prices of seven items fell and rates of remaining 30 goods recorded no change.Published in The Express Tribune, July 23rd, 2016.Like聽Busines adidas campus grise s on Facebook, follow @TribuneBiz聽on Twitter to stay informed and join in the conversation. Spectral Diagnostics Inc. has announced that the first interim analysis has been conducted on the initial 76 randomized patients in its EUPHRATES trial.The Data Safety and Monitoring Board (DSMB), consisting of experts in the fields of critical care medicine, infectious disease, nephrology, biostatistics and regulatory affairs, reviewed the totality of the data set for evidence of safety concerns, such as adverse events and/or adverse device effects, related t dunk homme o the use of the Toraymyxin cartridge.The results from the first interim safety analysis by the DSMB state that asics laufschuhe there are no safety issues to date concerning the application of the Toraymyxin cartridge to patients in the EU yeezys PHRATES trial.In addition, the results state that the EUPHRATES clinical protocol appears to be defining the correct target patient population for this study."We are making consistent progress with our pivotal Phase III trial," said Dr. Paul Walker, Chief Executive Officer of Spectral Diagnostics.Dr. Walker cont